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Abstract
Background: Oral corticosteroids and inhaled bronchodilators with or without antibiotics represent standard treatment of
COPD exacerbations of moderate severity. Frequent courses of oral steroids may be a safety issue. We wanted to evaluate in
an out-patient setting whether a 2-week course of inhaled budesonide/formoterol would be equally effective for treatment of
acute COPD exacerbations as standard therapy in patients judged by the investigator not to require hospitalisation.
Methods: This was a double-blind, randomised, non-inferiority, parallel-group, multicentre study comparing two treatment
strategies; two weeks' treatment with inhaled budesonide/formoterol (320/9 μg, qid) was compared with prednisolone (30 mg
once daily) plus inhaled formoterol (9 μg bid) in patients with acute exacerbations of COPD attending a primary health care
centre. Inclusion criteria were progressive dyspnoea for less than one week, FEV1 30–60% of predicted normal after acute
treatment with a single dose of oral corticosteroid plus nebulised salbutamol/ipratropium bromide and no requirement for
subsequent immediate hospitalisation, i.e the clinical status after the acute treatment allowed for sending the patient home.
A total of 109 patients (mean age 67 years, 33 pack-years, mean FEV1 45% of predicted) were randomized to two weeks' double-
blind treatment with budesonide/formoterol or prednisolone plus formoterol and subsequent open-label budesonide/
formoterol (320/9 μg bid) for another 12 weeks. Change in FEV1 was the primary efficacy variable. Non-inferiority was
predefined.
Results: Non-inferiority of budesonide/formoterol was proven because the lower limit of FEV1-change (97.5% CI) was above
90% of the efficacy of the alternative treatment. Symptoms, quality of life, treatment failures, need for reliever medication (and
exacerbations during follow-up) did not differ between the groups. No safety concerns were identified.
Conclusion: High dose budesonide/formoterol was as effective as prednisolone plus formoterol for the ambulatory treatment
of acute exacerbations in non-hospitalized COPD patients. An early increase in budesonide/formoterol dose may therefore be
tried before oral corticosteroids are used.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major health problem and cause of death and disability.
Most patients with COPD suffer from exacerbations,
which vary in severity and duration. Frequent exacerba-
tions result in further decline in lung function, quality of
life [1,2] and drive mortality [3]. In addition to intensified
therapy with bronchodilators, such as β2-agonists and
anticholinergics, oral corticosteroids represent standard
treatment for COPD exacerbations [4]. The value of oral
steroids has been widely recognised [5,6] but extending
the course beyond two weeks has not provided additional
clinical benefit [7]. High doses of nebulized budesonide
has also been successfully used for treatment of acute
COPD exacerbations in the emergency department [8,9].
Inhaled corticosteroids alone [10] and in combination
with long-acting β2-agonists [11-14] have been useful in
the treatment of patients with moderate to severe COPD,
particularly for prevention of severe exacerbations.
In randomized studies in hospitalized patients with acute
severe COPD exacerbations, but not requiring ventilation
for acute respiratory failure, treatment with budesonide/
formoterol in a single inhaler has been compared to
inhaled salbutamol on top of a standardized regimen of
exacerbation treatment [15] and to i.v. aminophylline and
prednisolone plus inhaled salbutamol [16]. The results of
these studies indicated that budesonide/formoterol is safe
and may be of clinical benefit to COPD patients with
acute exacerbations [15,16]. Large, controlled studies
were proposed to be performed to evaluate the value of
budesonide/formoterol in the treatment of acute COPD
exacerbations [17].
Little is known about COPD exacerbations in an out-
patient setting. Based on our experience up to 90% of all
COPD patients with exacerbations can be treated at pri-
mary health care centres and thereafter return home with
intensified therapy. It is self-explanatory that these exacer-
bations are milder than those treated in hospitals or emer-
gency departments. Published clinical studies in patients
with COPD exacerbations have been performed in hospi-
tals or in emergency departments. Therefore, we decided
to investigate treatment of COPD exacerbations in an out-
patient setting and in patients not requiring immediate
hospitalisation. To the best of our knowledge this is the
first study focused on this type of moderate severe exacer-
bations. Our hypothesis was that a high dose of the budes-
onide/formoterol combination could be as effective as
prednisolone plus formoterol for this type of acute exacer-
bations not requiring immediate hospitalisation.
The primary aim of the study was to compare two treat-
ment concepts. The aims were divided as follows: 1) to
assess whether 2-weeks' treatment with inhaled budeso-
nide/formoterol (Symbicort® forte Turbuhaler®), at a dose
of 320/9 μg qid (double the standard dose), is as effective
as a 2-week course of oral prednisolone plus inhaled for-
moterol for the ambulatory treatment of an acute exacer-
bation, and 2) to assess whether the initial 2-week
treatment would influence the rate of exacerbations dur-
ing a subsequent 12-week open-label treatment period
with the fixed combination of budesonide and formoterol
at a standard dose of 320/9 μg bid. A non-inferiority
design was selected because the aim was not to demon-
strate superiority, but rather to investigate whether
patients suffering acute exacerbations could be managed
as effectively with an inhaled corticosteroid/long-acting
β2-agonist combination as with the standard oral gluco-
corticosteroid therapy.
Methods
Patients
The target population for this study were current or previ-
ous smokers with a smoking history of ≥ 10 pack years,
aged ≥ 40 years, with moderate COPD corresponding to
GOLD stage IIa or IIb (as defined in GOLD guidelines at
the time of initiation of the study) and an established
diagnosis of COPD for ≥ 6 months prior to study entry.
Study centres were asked to include preferentially patients
they had taken care of before. Such patients with an actual
acute history of progressive dyspnoea and/or increase in
sputum production and/or sputum volume indicative of
an acute exacerbation during the week prior to the
unscheduled visit to the primary care centre were included
if, in the attending physician's opinion, treatment with a
course of oral corticosteroids was needed. This excluded
patients with mild exacerbations who could be treated
with antibiotics and/or an increase in bronchodilator use,
and patients requiring oxygen therapy and with a risk for
developing respiratory failure and therefore being admit-
ted to hospital for observation and further treatment.
Study design
This was a double-blind, double-dummy, randomised,
non-inferiority, parallel-group, multicentre study per-
formed at 29 primary health care centres and one hospi-
tal. All patients received acute treatment with ipratropium
bromide and/or salbutamol given by nebulisation or via a
pressurised metered dose inhaler attached to a large vol-
ume spacer, in combination with a single dose of an oral
glucocorticosteroid (prednisolone 30–50 mg or betame-
thasone 3–8 mg). This treatment was given in accordance
with guidelines for ambulatory treatment of acute COPD
exacerbations.
After the acute treatment patients were randomised in bal-
anced blocks (sealed envelopes) to the double-blind treat-
ment if their forced expiratory volume in one second
(FEV1) was 30–60% of predicted normal. FEV1 was meas-
ured after 15 minutes and up to 4 hours after the acute
treatment.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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Major exclusion criteria were a diagnosis of asthma,
forced expiratory volume in one second/forced vital
capacity (FEV1/FVC) ratio > 0.7, a previous COPD exacer-
bation within 30 days prior to the study, oxygen satura-
tion < 92% after the initial acute treatment, requirement
for oxygen therapy, a need for immediate hospitalisation
as judged by the investigator, treatment with any inhaled
corticosteroid in doses > 1000 μg/day at study entry, and
use of or need for treatment with a non-selective β-recep-
tor antagonist.
The randomised treatment was budesonide/formoterol
(Symbicort forte®  Turbuhaler®, AstraZeneca, Södertälje,
Sweden), 320/9 μg/dose, one inhalation four times daily
for 2 weeks, or to prednisolone (Prednisolon Recip, Recip
AB, Årsta, Sweden), 30 mg once daily, plus inhaled for-
moterol (Oxis® Turbuhaler®, AstraZeneca, Södertälje, Swe-
den), 9 μg twice daily for 2 weeks. Patients receiving
regular anticholinergics at study entry were allowed to
continue taking that medication during the entire study
period. Antibiotics could be prescribed if judged necessary
by the investigator.
Following the 2-week double-blind treatment period all
patients were treated with open-label budesonide/formot-
erol, 320/9 μg one inhalation twice daily for additional 12
weeks. Exacerbations, defined as worsening of COPD
requiring a course of oral steroids or hospitalisation, were
recorded. The first patient entered the study in September
2005 and the last subject completed it in July 2007.
Assessments
The patients visited their health care centre for assessment
at the end of weeks one and two, and at the end of the
open follow-up period. The primary efficacy variable was
the change in FEV1 from baseline to treatment for one and
two weeks measured at the health care centre. Other effi-
cacy variables were treatment failures, i.e. the number of
patients requiring additional medication due to disease
deterioration during the first 2 weeks, FEV1 measured
twice daily at home with a Piko-1® electronic peak flow
meter (Medica Pharma, Uppsala, Sweden), the number of
patients with an exacerbation and the time to first exacer-
bation during the follow-up period. Patients also recorded
daily symptoms (difficulty to breathe, cough, chest tight-
ness and night-time awakenings) on a scale from 0 to 4
and use of reliever medication (ipratropium bromide,
Atrovent®, inhalation powder, 40 μg per dose, Boehringer
Ingelheim). A self administered Clinical COPD Question-
naire (CCQ) [18] was completed at the start of the study,
after one week and at the end of the double-blind period.
Total individual scores on a scale from 0 to 6 were calcu-
lated, as were scores for the subgroups physical function,
mental health and symptoms. A difference of 0.4 was con-
sidered clinically important [19].
At all visits serum C-reactive protein (CRP) concentrations
were measured using a latex immunoassay (Aeroset® CRP
Vario, Abbott Scandinavia AB, Solna, Sweden).
Safety was monitored by reporting of adverse events, seri-
ous adverse events and discontinuations due to adverse
events.
The study was performed according to Good Clinical Prac-
tice and the Declaration of Helsinki. All local ethics com-
mittees approved the study protocol. All patients gave
their written informed consent for participation.
Determination of sample size
FEV1, being a robust endpoint in an ambulatory setting,
was used for power calculation. The sample size was cal-
culated to show non-inferiority of budesonide/formot-
erol. The null hypothesis was that mean values for the new
and the standard treatments were not equivalent and that
the lower limit of the one-sided 97.5% confidence inter-
val (CI) of budesonide/formoterol was not below 90% of
the effect shown with the standard treatment. With a sam-
ple size in each group of 43 completed patients, the power
was 80% with the common standard deviation of 0.170 of
the log-transformed FEV1.
Statistical analysis
The intention-to-treat principle was used, i.e. all patients
who received at least a single dose of study medication
were included in the analyses.
The primary analysis was a non-inferiority test as
described above in the sample size calculation. The prede-
fined non-inferiority limit of 90% was selected to be more
demanding than the 80% to 125% limits often used when
comparing pharmacological responses. The analysis was
performed by log transforming the FEV1 % predicted val-
ues using an analysis of covariance (ANCOVA) model
with the treatment and country as factors and log-trans-
formed baseline FEV1 % of predicted as a covariate. The
least-squared means resulting from this model were used
to calculate the one-sided 97.5% CI for the log-trans-
formed difference between the two treatments.
The secondary variables, CCQ and FEV1 measured at clinic
visits, were analysed by calculating the 95% CI for the
adjusted mean differences. The secondary diary card vari-
ables, morning FEV1, evening FEV1, intake of study drug,
use of reliever medication and COPD symptom scores
were analysed using an analysis of variance (ANOVA)
with treatment and country as factors. A non-inferiority
test was not used since that would have required prede-
fined non-inferiority limits for each variable.
The number of patients with treatment failures during the
2-week double-blind period were compared betweenRespiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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treatments. The analysis of exacerbations in the 12-week
open-label period was based on the number of patients
with exacerbations using a log-rank test.
Changes in serum CRP concentrations and safety data
were analysed using descriptive statistics.
Results
Study population
A total of 113 patients were randomised and 109 were
included in the analyses of efficacy and safety. The patient
characteristics and demographics at baseline are shown in
Table 1. The budesonide/formoterol group included more
female patients than the prednisolone plus formoterol
group. No other important differences between the study
groups were observed, including both previous mainte-
nance medications and acute treatment before study
entry.
Compliance analyses, based on the patients' diary card
recordings during the 2-week double-blind period,
revealed that the patients in the budesonide/formoterol
group used an average daily dose of 1151 μg of budeso-
nide of 1280 μg prescribed and 32.0 μg of formoterol of
36 μg prescribed. The patients in the prednisolone plus
formoterol group used 29.0 mg of prednisolone of 30 mg
prescribed and 17.3 μg of formoterol of 18 μg prescribed.
FEV1
The changes from baseline in clinic FEV1, as percentages of
predicted values, showed non-inferiority for combination
inhalation therapy (budesonide/formoterol) compared
with oral/inhalation treatment (prednisolone plus for-
moterol) (Figure 1). Non-inferiority was also observed
when analysed separately after treatment for 1 week and 2
weeks, respectively (Figure 1). FEV1 and FEV1 % predicted
at baseline and after treatment for one and two weeks are
shown in Table 2 as well as the percent change in FEV1
after treatment for one and two weeks.
The change in FEV1 % predicted from baseline was statis-
tically significant already at 1 week in the budesonide/for-
moterol group (p = 0.03), but not in the prednisolone
plus formoterol group (p = 0.17). After 2 weeks this
change was significant in both groups; budesonide/for-
moterol (p = 0.01) and prednisolone plus formoterol (p =
0.005).
Daily morning and evening FEV1 values during the 2-week
double-blind period, measured at home with the Piko-1
meter, are shown in Figure 2. No improvements from
baseline (first measurement at home in the morning and
evening respectively) were seen in either group. There
were no statistically significant differences in FEV1
between the two groups and the shapes of the curves over
the 2-week period look very similar.
Table 1: Patient baseline demographics and characteristics
Budesonide/formoterol
N = 55
Prednisolone + formoterol
N = 54
Age, years 67.2 (9.7) 66.7 (9.3)
Females, % 55% 43%
Time since COPD diagnosis, years 8.0 (5.7) 5.9 (4.3)
Current smokers, % 33% 28%
Pack-years (range) 33 (10–120) 33 (10–83)
Body mass index 25.2 (4.8) 26.0 (5.3)
FEV*, L 1.16 (0.34) 1.23 (0.37)
FEV1*, % predicted normal 45.1 (8.9) 45.0 (9.5)
FVC*, L 2.42 (0.73) 2.48 (0.70)
FEV1/FVC* ratio 0.49 (0.12) 0.51 (0.11)
GOLD classification (no. of patients)
I 11
IIa 28 33
IIb 26 18
III 02
SpO2 95.2 (1.7) 94.9 (1.6)
Maintenance medication at study entry†:
ICS + LABA + AC 24 20
ICS + LABA 10 9
ICS + AC 15
AC ± SABA/LABA 14 7
No medication 61 3
Mean dose of ICS,‡ μg/day 659 (267) 553 (241)
Data are presented as means and standard deviations. * Lung function measurements were performed 0.25–4 hours (mean 0.9 hours) after acute 
therapy; † ICS = inhaled corticosteroid; LABA = long-acting inhaled β2-agonist; AC = anticholinergics, SABA = short-acting inhaled β2-agonist; ‡ 
Mean ICS intake in patients with recorded ICS use.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
Page 5 of 11
(page number not for citation purposes)
Treatment failures
There were two treatment failures in the budesonide/for-
moterol group (one patient after 1 day requiring hospital-
isation for 5 days, and another after 5 days not requiring
hospitalisation). In both cases social factors not related to
the disease or randomized treatment appear to have been
involved. No treatment failures were reported in the pred-
nisolone plus formoterol group.
Use of reliever medication
On average, during the 2-week double-blind period, the
patients in the budesonide/formoterol and prednisolone
plus formoterol groups used 1.8 and 2.1 inhalations per
day of reliever medication, respectively. The difference
was not statistically significant. Separating the number of
reliever inhalations into day-time and night-time inhala-
tions yielded similar results.
COPD symptoms
There were no statistically significant differences in symp-
tom scores between the two groups (Figure 3).
Clinical COPD Questionnaire
The changes in total CCQ scores from baseline to week 1
and 2 visits were -0.72 and -0.9 in the budesonide/for-
moterol group and -0.77 and -1.09 in the prednisolone
plus formoterol group, respectively (Table 2). There were
no statistically significant differences between the groups;
neither in total CCQ scores, nor in subgroup scores for
function, mental health and symptoms.
Exacerbations
Neither the number of exacerbations nor the time to first
exacerbation differed significantly between the groups
during the 12-week open-label period, when all patients
received budesonide/formoterol. There were 11 patients
with 14 exacerbations (one hospitalisation) among 55
patients in the budesonide/formoterol group and 10
patients with 14 exacerbations (three hospitalisations)
among 54 patients in the prednisolone plus formoterol
group. The time to the first exacerbation is shown in Fig-
ure 4.
C-reactive protein concentrations
Mean serum CRP levels at baseline were higher in the
budesonide/formoterol group than in the prednisolone
plus formoterol group (19.8 mg/L, SEM 5.8 versus 12.2
mg/L, SEM 3.2). After both the 2-week double-blind
period and 12-week open-label period the mean serum
CRP levels were similar in both groups (Figure 5).
Safety
No safety concerns were raised in the study. In the budes-
onide/formoterol group 15 patients had 18 adverse events
and 14 patients had 15 adverse events in the prednisolone
plus formoterol group. These adverse events represented a
variety of preferred terms and were similar in the two
groups.
Discussion
In the present study two treatment concepts for ambula-
tory patients with COPD exacerbations were compared.
Out-patients making unscheduled visits to the health care
centre because of an acute moderate COPD exacerbation
not requiring immediate hospitalisation, but judged by
the investigator to require a course of oral corticosteroids,
were selected for the study. This study demonstrated that
budesonide/formoterol, taken four times daily and initi-
ated at the time of onset of the exacerbation was as effec-
tive as standard treatment with oral prednisolone plus
formoterol.
The baseline lung function data, smoking histories, the
fact that the patients were well known to the investigators
Table 2: FEV1 at clinic visits and Clinical COPD Questionnaire (CCQ) scores during the 2-week double-blind treatment period
Variable Time point Budesonide/formoterol Prednisolone + formoterol N*
FEV1, L Baseline 1.17 (0.35) 1.20 (0.36) 49/51
1 week 1.25 (0.45) 1.23 (0.34) 49/51
2 weeks 1.27 (0.43) 1.29 (0.40) 49/51
FEV1, change from baseline, % 1 week 6.84 (23) 2.50 (24) 49/51
2 weeks 8.55 (24) 7.50 (29) 49/51
FEV1, % predicted Baseline 44.8 (9.2) 44.4 (9.4) 49/51
1 week 47.4 (12.1) 46.0 (11.3) 49/51
2 weeks 48.3 (12.0) 47.9 (12.4) 49/51
CCQ, score 0–6 Baseline 3.30 (0.95) 3.35 (1.02) 45/51
1 week 2.67 (1.25) 2.58 (1.11) 45/51
2 weeks 2.52 (1.19) 2.32 (1.11) 45/51
Data are presented as means and standard deviations. * Refers to patients in the budesonide/formoterol and prednisolone + formoterol groups, 
respectively with recordings at all visits.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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and the exclusion of patients with a diagnosis of asthma
strongly support the COPD diagnosis in the included
patients. An exacerbation of COPD has been defined as a
sustained worsening from a stable state and beyond nor-
mal day-to-day variation, which is acute in onset and may
necessitate a change in regular medication [20]. In long-
term clinical trials a variety of different definitions for
COPD exacerbations have been used [21]. However, in
studies dealing with acute exacerbations as an inclusion
criterion the definition is generally based on the patient's
clinical history during the past few days. The patients in
our study fulfilled clinical COPD exacerbation criteria as
they all reported increasing symptoms prior to the
unscheduled first study visit to the primary care centre.
The occurrence of an exacerbation is supported by the ele-
vated serum CRP levels at the time of randomisation and
a poor quality of life as previously described during an
acute exacerbation [22]. In fact, the mean CCQ score at
onset of the exacerbations was slightly worse in our study
(mean CCQ score 3.3) than in the study by Bourbeau et al
who reported a mean CCQ score of 3.0 [21].
It could be argued that the lack of a placebo arm is a lim-
itation of this study and that a similar effect of the two
treatments may reflect a lack of a clinical effect of either
treatment. However, as it has been clearly and indisputa-
bly shown in placebo-controlled trials that glucocorticos-
teroids are beneficial in patients with COPD
exacerbations [4-6,23,24], it was considered unethical to
include a placebo group in the present study. As this study
included only patients who had a deterioration of their
clinical status during the last week prior to entry, and as
there was a subsequent improvement in all evaluated
parameters and a decrease in initially elevated CRP levels,
Change in FEV1 as % predicted, measured at the clinic, from baseline to one and two weeks for all patients (main graph) and log  ratio between treatments (inset graph) Figure 1
Change in FEV1 as % predicted, measured at the clinic, from baseline to one and two weeks for all patients 
(main graph) and log ratio between treatments (inset graph). Data are presented as means and ± 95% CIs. * The 
treatment with budesonide/formoterol was non-inferior to the standard treatment with prednisolone plus formoterol because 
the predefined limit of at least 90% effect with budesonide/formoterol was superseded by the value (92.0%) of the lower limit 
of the 97.5% CI. The mean effect of budesonide/formoterol was 99.4% of standard treatment and the upper 97.5% CI limit was 
107.4%.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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we believe that there was a true clinical effect in both
groups.
It could also be discussed whether all treatment effects
were due to the initial single dose of oral steroid plus the
nebulisation of bronchodilators. However, for safety rea-
sons we found it hard not to give this treatment as the aim
was to send all patients home for further randomized
treatment and not to consider hospitalisation. Secondly,
this acute treatment was given to all patients and it
appears unlikely that a carry-over effect would have lasted
for the duration of the study.
The comparator treatment in our study was oral pred-
nisolone plus inhaled formoterol. We considered the
duration of the prednisolone course (2 weeks) to be ade-
quate because prolongation of prednisolone therapy to
eight weeks has previously been shown to add no clinical
benefit [7].
There was an improvement in FEV1 of 8–9% and in FEV1
predicted normal of approximately 3% in both groups.
The improvement was already statistically significant at 1
week with budesonide/formoterol and after 2 weeks for
both treatments. The small improvement in FEV1 could be
regarded as clinically irrelevant, but it should be noted
that the observed improvements in FEV1 were on top of
baseline values obtained after acute treatment with neb-
ulised bronchodilators and systemic corticosteroids at
study entry. In addition to similar effects on lung function
in both groups, several secondary and clinically more rel-
evant efficacy variables, such as symptoms, quality of life
and need for reliever medication, were found to be
equally improved in the budesonide/formoterol group
and the prednisolone plus formoterol group. The occur-
rence of two treatment failures in the budesonide/formot-
erol group does not alter this conclusion as these were
clearly unrelated to the randomized treatment.
The doses of inhaled formoterol differed during the dou-
ble-blind period; patients in the budesonide/formoterol
group used a mean of 32 μg per day, whereas the patients
in the prednisolone plus formoterol group used on
average17.3 μg per day. It is possible that the higher for-
moterol dose may have resulted in a more pronounced
effect on lung function since a dose-response relationship
for FEV1 in stable COPD patients has been demonstrated
with formoterol [25]. However, it is not known whether a
Change in FEV1 as % of predicted from daily measurements at home during the double-blind period Figure 2
Change in FEV1 as % of predicted from daily measurements at home during the double-blind period. Bars to the 
right are presented as means and ± 95% CIs.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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dose-response applies also for treatment of exacerbations.
As the formoterol doses of both treatment groups were
rather high it seems reasonable to assume that the differ-
ence in doses probably had no or only a marginal influ-
ence on the results.
The results of our study can be compared to the results of
the only so far reported study with budesonide/formot-
erol in COPD patients and acute exacerbations, although
reported only as an abstract [16]. This study was per-
formed in hospitalized patients with baseline mean FEV1
values around 0.85 L. The patients in our study were out-
patients with mean FEV1 values above 1.15 L after acute
treatment with a single dose of oral prednisolone plus
nebulized bronchodilators, and from the beginning con-
sidered able to return home after the acute treatment.
Therefore, our patients may have represented a milder
type of COPD exacerbations. However, as the patients'
baseline per cent of predicted FEV1 values are unknown in
the study by Cazzola et al [16] it is hard to more precisely
compare the study populations. The efficacy, reported at
72 hours, of budesonide/formoterol 160/4.5 μg × 4 every
6 hours measured as improvements in FEV1 was statisti-
cally significant in the study by Cazzola et al [16] and not
different from the improvements in the comparator group
receiving aminophylline 240 mg and prednisolone 20 mg
i.v. every 12 hours plus inhaled salbutamol 400 μg every
6 hours. However, a comparison of the effect level is also
difficult as we report results after treatment for one and
two weeks and the observation time in the study by Caz-
zola et al was 72 hours [16].
The main purpose of using an inhaled medication as one
of the treatment options was the idea of testing a medica-
tion that in the future could be part of a self-management
plan for out-patients with not too severe exacerbations.
The difference in the way the corticosteroid component
was administered may have played an important role for
the results. Although the daily dose of budesonide was
not higher than 1280 μg (delivered dose via Turbuhaler
corresponding to 1600 μg of a metered dose) this dose in
patients with stable COPD has been found very effective
[26]. From a safety point of view, however, this dose
causes significantly less effects on e.g. the pituitary-adre-
nal axis than the comparator dose of 30 mg prednisolone
[27].
Change from baseline in four COPD symptom scores during double-blind treatment: difficulty in breathing, cough, chest tight- ness and night-time awakenings Figure 3
Change from baseline in four COPD symptom scores during double-blind treatment: difficulty in breathing, 
cough, chest tightness and night-time awakenings. Bars to the right are means and ± 95% CIs. Lower values represent 
improvements.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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A clinically valuable observation from our study was that
the dry powder inhaler, Turbuhaler, functioned well in
patients with acute COPD exacerbations. This observation
supports the results of an earlier study, performed in an
emergency room setting, where patients with COPD
responded equally well to formoterol administered via
Turbuhaler and formoterol given using a pressurised
metered dose inhaler attached to a spacer [28].
Based on the results of earlier studies [7,22,29] we consid-
ered a 3-month follow-up period to be sufficient to evalu-
ate the incidence of further exacerbations. Time to first
exacerbation and the number of exacerbations during the
follow-up period, when all patients were treated with the
approved standard dose of budesonide/formoterol, were
almost identical in the two groups, showing that the ini-
tial budesonide/formoterol treatment did not influence
the long-term outcome compared with initial treatment
using prednisolone plus formoterol.
CRP is recognised as a marker of systemic inflammation
[30] and patients with worsening of COPD have higher
serum CRP levels than healthy control subjects [31]. In
this study, CRP at baseline was higher in the budesonide/
formoterol group than in the prednisolone plus formot-
erol group, probably indicating more severe systemic
inflammation in this group. The decrease in serum CRP
observed in the budesonide/formoterol group cannot be
explained by the high formoterol doses because β2-ago-
nists do not influence serum CRP levels [32]. The demon-
stration that budesonide/formoterol and prednisolone
plus formoterol decrease serum CRP levels to the same
extent is in agreement with an earlier study which showed
a marked reduction in serum CRP levels in stable COPD
patients treated with inhaled corticosteroids [32]. The
equivalence of the CRP decline in the two treatment
groups is suggestive of equal efficacy of the two treat-
ments.
The risk of systemic side effects when using oral pred-
nisolone – even short courses – has been well recognised
[33] and the total steroid burden may be heavy in patients
with frequent exacerbations. Short-term increases in the
doses of inhaled budesonide have been found safe and
well tolerated [27,34]. Thus, from a safety standpoint,
treatment of acute COPD exacerbations using inhaled
medications would constitute a clear advantage over ther-
apy with oral corticosteroids.
Conclusion
Treatment of acute exacerbations of non-hospitalized
COPD patients with an elevated dose of the fixed combi-
Time to first exacerbation during the open-label treatment period Figure 4
Time to first exacerbation during the open-label treatment period. Day 0 corresponds to the end of the double-blind 
treatment period. The groups shown represent the treatment arms for the double-blind treatment period.Respiratory Research 2009, 10:11 http://respiratory-research.com/content/10/1/11
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nation of budesonide/formoterol is as effective as a stand-
ard treatment with an oral corticosteroid plus formoterol.
Being a safe alternative by avoiding courses of oral ster-
oids, treatment with budesonide/formoterol in patients
with these moderate severe COPD exacerbations may
therefore be a clinically important alternative for physi-
cians working in primary health care centres. Carefully
designed controlled trials should be performed to assess
whether increasing the dose of the fixed combination,
early in the course of symptom deterioration, is beneficial
when used as part of a self-management approach.
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